Hamartin and tuberin are products of the tumor suppressor genes TSC1 and TSC2, respectively. Mutations affecting either gene result in the tuberous sclerosis syndrome, a neurologic genetic disorder characterized by the formation of multiple benign tumors or hamartomas. In this study, we report the identification of TSC2, but not TSC1, as a substrate of HtrA1, a member of the human HtrA family proteins of serine proteases. We show the direct interaction and colocalization in the cytoplasm of HtrA1 and TSC2 and that HtrA1 cleaves TSC2 both in vitro and in vivo. Finally, we show that alterations in HtrA1 expression cause modifications in phosphorylation status of two downstream targets of TSC2: 4E-BP1 and S6K. Our data suggest that, under particular physiologic or pathologic conditions, HtrA1 degrades TSC2 and activates the downstream targets. Considering that HtrA1 levels are significantly increased during embryogenesis, we speculate that one of the targets of HtrA1 activity during fetal development is the TSC2-TSC1 pathway. Mol Cancer Res; 8(9); 1248-60. ©2010 AACR.
Introduction
HtrA1 is the first identified member of the human HtrA family proteins, a group of heat shock-induced serine proteases involved in several aspects of protein quality control and cell fate. This family consists of four members (HtrA1, HtrA2, HtrA3, and HtrA4), which share a highly conserved trypsin-like serine protease domain and one PDZ domain at the COOH terminus (1) , and specific distinct regulation domains, in relation with their physiologic functions, at the NH 2 terminus.
Structurally, the NH 2 terminus of HtrA1 shares a signal sequence for secretion and two homology domains: the first region of the protein is homologous to mac25, a gene product related to insulin-like growth factor-binding protein (2) , and to follistatin, an activin-binding protein (3) , and the second domain shows homology >40% to bacterial serine protease and allows its proteolytic activity (4) . Among these two regions, there is a Kazal-type inhibitor motif. Therefore, the human HtrA1 protein is a secreted serine protease that exhibits endoproteolytic activity, including autocatalytic cleavage. It is also known that conversion by site-directed mutagenesis of the putative conserved active site Ser 328 to alanine eliminates this enzymatic activity (4) . Until now, several targets of HtrA1 have been identified, most of which are extracellular proteins. These include components of extracellular matrix, such as type III collagen (5) and fibronectin (6) , or components of cartilage, such as aggrecan, decorin, and fibromodulin (7) . Moreover, it has been described that purified HtrA1 degrades various amyloid precursor protein fragments, including amyloid-β and its precursor, the C99 peptide, both involved in a metabolic balance able to prevent plaque formation in the brain of Alzheimer's disease patients (8) .
In accordance with its proteolytic activity and extracellular localization, HtrA1 was initially described as a gene downregulated in SV40-trasformed human fibroblasts (9) and overexpressed in osteoarthritic cartilage (4) . Subsequently, it has been reported that the expression of HtrA1 is also decreased in progression and invasion of melanomas, ovarian cancers, lung cancer, and mesotheliomas (10) (11) (12) (13) . It has been shown that its overexpression inhibits cell growth and proliferation in vitro and in vivo, thus suggesting a possible role as a tumor suppressor (10) . Moreover, it seems that molecular alterations associated with the expression of this HtrA1 serine protease may play an important role in tumor behavior and response to chemotherapy (14) . Recently, several studies revealed the involvement of HtrA1 also in age-related macular degeneration. Genome-wide linkage analyses showed a strong association of a variant of HtrA1 gene with increased susceptibility to age-related macular degeneration in different populations (15) (16) (17) (18) (19) .
To identify new HtrA1-binding partners and thereby obtain new clues toward the functions of this protein, we have used the enzymatically inactive form of HtrA1, called HtrA1-S328A, as a bait in a yeast two-hybrid screening experiment. Among the proteins identified as possible partner of HtrA1, we found one of the two proteins involved in the pathogenesis of tuberous sclerosis, a 1,807-amino acid/220-kDa protein called TSC2.
Tuberous sclerosis complex (TSC) is a rare inheritable disorder characterized by the development of hamartomas in the brain and in other vital organs such as kidneys, heart, eyes, lungs, and skin. The growth of benign tumors is frequently associated with skin rashes, seizures, mental retardation, and renal dysfunction (20) (21) (22) .
Two tumor suppressor genes responsible for TSC have been identified: TSC1 located on chromosome 9q34 and TSC2 on 16p13, encoding hamartin and tuberin, respectively (23, 24) .
It has been elucidated that TSC1 and TSC2 physically interact to form an intracellular heterodimer (TSC1/TSC2 complex) participating in the control of cell growth and division (25, 26) . This TSC complex acts upstream of the mammalian target of rapamycin (mTOR), a serinethreonine kinase that increases cell growth and proliferation. Activation of mTOR leads to increased protein synthesis through phosphorylation of two effector molecules: p70S6K and 4E-BP1. p70S6K, the ribosomal protein S6 kinase I, can phosphorylate translational regulators, such as eukaryotic initiation factor eIF4B, to enhance the translational efficiency of several mRNAs (27, 28) . 4E-BP1, the eukaryotic initiation factor 4E-binding protein 1, is able to interact with the eukaryotic translation initiation factor eIF4E. Binding of the 4E-BPs to eIF4E is regulated by phosphorylation: Hypophosphorylated 4E-BP1 isoform interacts strongly with eIF4E to prevent translation initiation. On phosphorylation by the TOR kinase, 4E-BP1 releases eIF4E and translation initiation ensues (29) . When the TSC complex is active, usually under conditions that are adverse for proliferation, it is able to inhibit mTOR through the inhibition of Rheb, a member of the Ras superfamily of GTPases, important for the progression from G 0 to G 1 phase. Therefore, inhibition of mTOR activity leads to prolonged G 1 phase or arrest in G 1 (27) . On insulin or growth factor stimulation, TSC2 is phosphorylated by several kinases, including Akt/PKB (a serine-threonine kinase involved in cellular survival pathways) and RSK1 (p90 ribosomal S6 kinase 1), thereby suppressing its GTPase-activating protein activity (30) . As a consequence, the TSC complex is no more functional, and downstream targets of mTOR act together to increase protein synthesis and cell growth. Mutations in TSC1 or TSC2 genes lead to constitutive activation of this pathway; as a consequence, mTOR uncontrolled activity triggers cell cycle progression and tumor formation (27) .
To the best of our knowledge, TSC2 is the first cytoplasmic target of HtrA1 identified until now. In this article, we have characterized in vitro and in vivo the interaction between these two proteins.
Materials and Methods

Plasmids and DNA constructs
Human wild-type HtrA1 cDNA was a kind gift of Dr. Trueb (University of Bern, Bern, Switzerland). The truncated expression constructs encoding the mac25 domain (amino acids 22-155), the KI domain (amino acids 97-155), and the COOH-terminal HtrA (amino acids 150-480) were generated by PCR.
The HtrA1-S328A variant expression cDNA was obtained by site-directed mutagenesis of the original HtrA1 expression construct using the Stratagene QuikChange kit as previously described (4) .
For transfection experiments, the full-length HtrA1 and its variant HtrA1-S328A cDNAs were cloned as EcoRI/ BamHI fragments into pcDNA3T7Tag mammalian expression vector (Invitrogen).
For production of the glutathione S-transferase (GST)-HtrA1 recombinant fusion protein, the full-length HtrA1 (HtrA1-S328A) and the COOH-terminal truncated fragments (HtrA, mac25, and KI) were cloned as EcoRI/BamHI fragments into the pGEX2TK vector (Invitrogen).
The full-length TSC1-pcDNA3.1 and TSC2-pcDNA3.1 expression constructs were kindly provided by Dr. Halley (Erasmus Medisch Centrum, Rotterdam, the Netherlands). Truncated TSC2 cDNAs were obtained by PCR using TSC2-pcDNA3.1 as template and specific primers: TSC2 (1-607), 5′-GATCGGATCCATGGCCAAACCAACAAG-CAAAGAT-3′ (forward) and 5′-GATCTCGAGCT-CACGCGATTGGCAGGGTGTAGCT-3′ (reverse); TSC2 (607-1099), 5′-GATCGGATCCATGGCGAG-CAGCATCCGGCTG-3′ (forward) and 5′-GATCTC-GAGCTCACCCGGGGCTGGAGCTCGA-3′ (reverse); TSC2 (1099-1807), 5′-GATCGGATCCATGGGGGTG-CATGTGAGACAGACC-3′ (forward) and 5′-GATC-TCGAGCTCACACAAACTCGGTGAAGTCCTC-3′ (reverse).
All these truncated TSC2 cDNAs were cloned as EcoRI/ SacI fragments into pcDNA3.1 expression vector. All of the constructs were sequenced completely.
Antibodies
The TSC1 and TSC2 polyclonal antibodies used in this study were purchased from Santa Cruz Biotechnology and used at the manufacturer's recommended dilutions. The anti-T7Tag monoclonal antibody was from Novagen. The anti-4E-BP1 antibody was from Cell Signaling. Anti-phospho-ribosomal S6 kinase (p-S6K) and anti-total S6K antibodies were from Santa Cruz Biotechnology. The rabbit polyclonal antiserum raised against HtrA1 has been previously described (10) . To normalize each Western blot experiment, we used the anti-β-actin antibody from Santa Cruz Biotechnology.
Yeast two-hybrid selection
The HtrA1-S328A cDNA was cloned into the EcoRI/ BamHI sites of vector pGBKT7 (BD Clontech) in frame with the GAL4-binding domain. The yeast strain AH109, carrying UAS-His3, UAS-LacZ, and UAS-ADE2 reporter genes, was cotransformed with the pGBKT7-HtrA1-S328A bait and with a human fetal brain cDNA library (BD Clontech) fused to the GAL4 activation domain in the pACT2 vector (BD Clontech). Transformation was carried out using the lithium acetate method. Cells were plated on minimal synthetic defined medium (BD Clontech) supplemented with the required bases and amino acids and lacking tryptophan (Trp), leucine (Leu), histidine (His), and adenine (Ade). Plates were incubated for 7 days at 30°C, and then His + Ade + transformants were isolated. The His + Ade + colonies, replica plated on SD-Leu-TrpHis-Ade medium and LacZ + , were identified by a filterlifting assay for β-galactosidase activity. Plasmid DNA was prepared from candidate clones and transformed into Escherichia coli XL1-Blue cells (Stratagene). Recovered library-derived plasmids were analyzed by DNA sequencing.
In vitro binding assay, GST pull-down assay, and mapping experiment GST fusion protein expression was induced for 3 hours in a 500-mL culture of E. coli BL21 by the addition of 1 mmol/L isopropyl-L-thio-B-D-galactopyranoside. The bacterial pellet was resuspended in 20 mL of NENT buffer [20 mmol/L Tris-Cl (pH 8.0), 100 mmol/L NaCl, 1 mmol/L EDTA, 0.5% NP40, 1 mmol/L phenylmethylsulfonyl fluoride, 10 μg/mL leupeptin] or NENT buffer added with 2% Sarkosyl (for insoluble protein) and sonicated thoroughly (10 × 30 seconds). After gentle mixing for 30 minutes at 4°C, the lysate was spun at 12,000 × g for 10 minutes at 4°C. The induced GST fusion protein in the supernatant fraction was bound to 250 mL of prewashed glutathione-Sepharose beads (Amersham Pharmacia Biotech) for 60 minutes at 4°C. The beads were washed extensively with NENT buffer to remove nonspecifically bound bacterial proteins, and the quantity and purity of the GST fusion protein bound to the glutathioneSepharose beads were analyzed by SDS-PAGE.
For the in vitro binding assay, 1 μg of pcDNA3.1 encoding TSC1 or TSC2 was used to program a TnT rabbit reticulocyte lysate (Promega) under the control of the T7 polymerase in the presence of [ 35 S]methionine (Amersham Pharmacia Biotech). Aliquots of the reaction mixture were added to glutathione-Sepharose beads (Amersham Pharmacia Biotech) coupled with 5 μg of GST-HtrA1wt, GSTmac25, GST-KI, and GST-HtrA. Incubation was carried out in NENT buffer for 60 minutes at 4°C with gentle rocking. Beads were washed three times in NENT buffer, and electrophoresis was done on 6% acrylamide SDS-PAGE. Gels were dried and exposed at −70°C using Kodak Biomax MS films.
For the mapping experiment, 1 μg of plasmid encoding for the different truncated expression constructs of TSC2 [TSC2 (1-607), TSC2 (607-1099), and TSC2 (1099-1807)] was used for in vitro translation as described above. The same amount of each in vitro-translated constructs was incubated with GST-HtrA1wt (5 μg) or with GST alone as control for 60 minutes at 4°C with gentle rocking.
After washing, the beads were analyzed on 6% acrylamide SDS-PAGE.
To do a GST pull-down assay with endogenous TSC2 and TSC1 from cell extracts, an equal amount of GST or GST-HtrA1wt protein (5 μg) and 500 μg of Phoenix cell lysate were used for the assay. The mixture of GSTHtrA1wt beads and cell lysate was incubated with rotation at 4°C for 3 hours. Then, the beads were washed three times with lysis buffer. The complexes were separated on 6% SDS-PAGE. Western blot was done with specific anti-TSC2 or anti-TSC1 antibodies.
Cell culture, transfection, and Western blot analysis
Phoenix cells were kept in DMEM supplemented with L-glutamine, 10% heat-inactivated fetal bovine serum, and penicillin-streptomycin. A375P and A375M cell lines were cultured in RPMI 1640 supplemented with L-glutamine, 10% heat-inactivated fetal bovine serum, and penicillinstreptomycin. LM cell line was cultured in RPMI 1640 as described elsewhere (31) .
For transfection experiments, Phoenix cells were seeded into 10-cm culture dishes and grown overnight to a confluence of 60% to 80%. Expression constructs were transfected into the cells using standard calcium phosphate protocols. The LM, A375P, and A375M cells were seeded into 10-cm culture dishes and grown overnight to a confluence of 80% to 90%. Expression constructs were transfected using Lipofectamine 2000 transfection reagent (Invitrogen) following the protocol instructions.
Twenty-four hours after transfection, the cells were harvested and lysed in lysis buffer [50 mmol/L Tris-Cl (pH 7.4), 5 mmol/L EDTA, 250 mmol/L NaCl, 50 mmol/L NaF, 0.1% Triton X-100, 0.1 mmol/L Na 3 VO 4 , 1 mmol/L phenylmethylsulfonyl fluoride, 10 μg/mL leupeptin] for 30 minutes on ice. Lysates were centrifuged at 14,000 × g for 10 minutes at 4°C. Protein concentration was determined by the Bradford assay (Bio-Rad) at 595 nm. Proteins were denatured by boiling in Laemmli sample buffer (Bio-Rad) and resolved in SDS-PAGE. Gels were transferred to Immobilon P membrane (polyvinylidene difluoride; Millipore) and probed with the indicated antibodies.
A2780 ovarian cancer cell line was used to produce stable clones expressing HtrA1 as described elsewhere (32); SKOV3 and TOV21G ovarian cancer cell lines were used to produce HtrA1 short hairpin RNA (shRNA) stable clones as described elsewhere (33) .
Coimmunoprecipitation assay
For the immunoprecipitation experiment, 800 μg of Phoenix cell lysate transfected with pcDNA3T7Tag-HtrA1 were incubated with 1 μg of anti-T7Tag monoclonal antibody (to pull down HtrA1) or 1 μg of anti-TSC2 polyclonal antibody (to pull down TSC2) on ice for 15 hours before the addition of 30 μL of 50% protein G-Sepharose suspension (Amersham Pharmacia Biotech). As a control, 800 μg of lysate were incubated with a monoclonal antibody against p21 protein (BD Pharmingen) or a polyclonal antibody against Rb protein (Abcam). After gentle rotation for 90 minutes at 4°C, the beads were washed three times with lysis buffer before being analyzed by immunoblotting. A specific anti-TSC2 was used in Western blot to detect TSC2 protein bound to HtrA1 after immunoprecipitation with T7Tag antibody. To detect the amount of HtrA1 pulled down with anti-TSC2 antibody in Western blot, we used ExactaCruz IP/Western B kit (Santa Cruz Biotechnology) to eliminate the detection of heavy and light chains of the immunoprecipitation antibody (the size of HtrA1 is the same of the heavy chains of immunoglobulin).
Subcellular localization of HtrA1 with immunoelectron microscopy
Full-term placentas (n = 15) were collected, cut into pieces of <1 mm 3 , and fixed in 2.5% glutaraldehyde in phosphate buffer (pH 7.3) for 2 hours. Tissues were postfixed in osmium tetroxide (4%), dehydrated through graded concentrations of ethanol and propylene oxide, and subsequently embedded in Epon 812. For the immunogold technique, tissues were fixed only in 2.5% glutaraldehyde in phosphate buffer (pH 7.3). Ultrathin sections were cut from blocks and mounted on copper grids for the inspection of morphology or on nickel grids for immunogold. All sections were etched on drops of 3% hydrogen peroxidase for 10 minutes to permeabilize the resin. Tissue sections were washed in microfiltered distilled water and floated for 30 minutes on a drop of background blocking solution [0.05 mol/L Tris-HCl (pH 7.4), 0.1% bovine serum albumin (BSA)]. Grids were then incubated at 4°C overnight with a rabbit polyclonal antiserum raised against HtrA1 (10) at 1:10 dilution. After several rinses to remove excess antibody, the grids were incubated with an anti-rabbit antibody conjugated with 10-nm gold particles used as a secondary antibody at 1:100 dilution in diluent for gold-absorbed antibody [0.05 mol/L Tris-HCl buffer (pH 8.2), 1% BSA] for 1 hour. The grids were contrasted with lead citrate and uranyl acetate as for conventional electron microscopy. A preimmune serum was used as a negative control. The sections were observed by means of a Siemens Elmiskop IA electron microscope.
Colocalization analysis with immunofluorescence
Phoenix cells transfected with pcDNA3T7Tag-HtrA1 were grown on glass coverslips in Petri dishes. Cells were fixed in 3.7% formaldehyde for 15 minutes at 4°C and permeabilized in PBS containing 0.1% Triton X-100 for 5 minutes. Fixed cells were preincubated in 20% FCS for 30 minutes at 37°C in a humidified chamber. The following primary antibodies were used: mouse anti-T7Tag (Novagen) and rabbit anti-TSC2 (Santa Cruz Biotechnology). After 1-hour incubation, cells were washed three times in 0.1% Tween/PBS and further incubated for 30 minutes with anti-mouse Texas red-conjugated antibody (Vector Laboratories) to detect HtrA1T7Tag and anti-rabbit fluorescein-conjugated antibody (Jackson ImmunoResearch Laboratories) to detect TSC2. Cell spreads were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; 0.1 g/mL in distilled water) and mounted in Vectashield (Vector Laboratories). Images were taken using an Olympus AX70 microscope configured for epifluorescence and equipped with a cooled camera device.
Protein phosphatase treatments
Phoenix cells were lysed in protein phosphatase 1 (PP1) lysis buffer [50 mmol/L Tris-HCl (pH 7.4), 5 mmol/L EDTA, 250 mmol/L NaCl, 0.1% Triton X-100] as described above. PP1 (10 units; New England Biolabs, Inc.) and MnCl 2 (1 mmol/L final concentration) were added to the lysate, which was subsequently incubated for 60 minutes at 30°C. As a control, the lysate was incubated for 60 minutes at 30°C without PP1.
To investigate whether the phosphatase activity prevents the interaction between HtrA1 and TSC2, 500 μg of treated cell lysates were added to 5 μg of GST-HtrA1 beads (or GST beads as control) and mixed by gentle rotation for 1 hour at 4°C. The beads were recovered by centrifugation, washed three times with lysis buffer, and dissolved in SDS-PAGE loading buffer for the immunoblot analysis.
Purification of recombinant HtrA1 and proteolytic enzyme assessment
Purified recombinant HtrA1 was produced as described (8) . One microgram of TSC2-pcDNA3.1 was transcribed and translated in vitro in the presence of [ The translation product was buffered with the digestion buffer [50 mmol/L Tris-HCl (pH 8.5), 150 mmol/L NaCl] using Microcon Y10 filter (Millipore). Purified HtrA1 (5 μg) was added to the labeled TSC2 35 S eluted (Vf = 50 μL), and the digestion was done in digestion buffer at 37°C for 16 hours. As a positive control, 5 μg of purified HtrA1 were incubated with 10 μg of purified fibronectin in the same condition of the sample. As a negative control, 0.5 μg of BSA (Promega) was incubated with 5 μg HtrA1. The proteins were resolved in SDS-PAGE and stained with Coomassie Brilliant Blue R-250. Finally, the gel was dried and exposed for autoradiography to detect the digestion products.
Expression analysis of different factors involved in TSC2 pathway
Two different types of melanoma cell lines, A375 (primary and metastatic of the same cell type) and LM, were transfected with pcDNA3T7Tag-HtrA1, pcDNA3T7Tag-HtrA1-S328A, and empty vector as a control as described above. Lysate of transfected cells was run on gel to make Western blot using different antibodies against proteins involved in TSC pathway. Each experiment has been done at least three times and individually normalized using the antibody against β-actin.
Expression levels of HtrA1, TSC2, p-S6K, and total S6K were analyzed by immunoblot analysis in stable clones overexpressing HtrA1 (A2780 cells) or in stable clone with HtrA1 shRNA (SKOV3 and TOV21G cells). Empty vector-transfected cells and nontargeted control shRNAtransduced cells served as controls. The protein in the insoluble fraction was used for the analysis of the proteins. SKOV3 or TOV21G batch clonal cells with HtrA1 shRNA were seeded at 5 × 10 5 per well into six-well plates and cultured until cells became confluent. Following washing with 1.5 mmol/L Na 3 VO 4 in PBS twice, the cells were placed on ice and the protein lysate was extracted with 0.5 mL of lysis buffer [10 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, 0.2% NP40, 1.5 mmol/L Na 3 VO 4 ], and cocktail protein inhibitor was added into each well. Two minutes later, soluble fraction was removed by centrifugation and the insoluble fraction was subjected to Western blot analysis.
Results
Identification of TSC2 as a binding partner of HtrA1
To identify new proteins able to interact with HtrA1, we did a yeast two-hybrid screening experiment on ∼5 × 10 5 clones from the human fetal brain cDNA library (Clontech). As a bait, we used the construct encoding full-length HtrA1-S328A, which lacks proteolytic activity and does not exhibit autoproteolysis (4) , to avoid the digestion of possible targets of our protease during the screening in yeast. From the 77 colonies that grew on selective medium, 52 were positive in a β-galactosidase selection assay, and 25 clones were recovered from yeast and then transformed into XL1-Blue-competent cells. Individual clones were screened and sequenced using the primers from vector. Among rescued plasmids, we found two clones with the cDNA of the tumor suppressor gene TSC2. The region obtained within the positive plasmids was the NH 2 -terminal part of TSC2; this finding suggested that the interaction between TSC2 and HtrA1 might take place in this region.
Confirmation of HtrA1/TSC2 binding in vitro
To verify the interaction between HtrA1 and TSC2 and to determine whether this association was specific, we did an in vitro binding assay. The activity of TSC2 in the cell is strictly dependent by its interaction and binding with TSC1, the other member of the TSC complex; the dimer acts as a tumor suppressor only when both the proteins are functional and are able to interact with each other (34) . Therefore, we decided to investigate whether HtrA1 is able to interact also with TSC1.
Both TSC1 and TSC2 were translated in vitro in the presence of [ 35 S]methionine and incubated with GSTHtrA1wt construct and with the truncated constructs encoding three different domains of HtrA1: GST-mac25, GST-KI, and GST-HtrA (Fig. 1A) . We used GST alone as a control. Washed beads were used to detect the presence of TSC2 or TSC1 on acrylamide SDS-PAGE; gels were dried and exposed at −70°C.
As shown in Fig. 1B , TSC2 coprecipitated with GSTHtrA1wt and GST-mac25, but not with GST-HtrA; moreover, there was a weak interaction also between TSC2 and GST-KI, the small domain included inside mac25. This indicates that HtrA1 interacts with TSC2, and the site of the binding of TSC2 on HtrA1 is into the mac25 domain of the serine protease. Finally, no TSC1 was retained by GST-HtrA1wt in this experiment (Fig. 1C) , thus excluding the hypothesis of a possible interaction of HtrA1 with the other member of the TSC complex.
To further investigate the association between HtrA1 and TSC2, a GST pull-down assay to precipitate TSC2 from cell extracts was carried out. To this end, a cleared lysate from Phoenix cells, expressing endogenous levels of TSC2, was applied to glutathione-Sepharose beads alone or to glutathione-Sepharose beads bound with the GSTHtrA1wt chimeric construct. As shown in Fig. 2A , endogenous TSC2 retained by the GST-HtrA1wt beads was detected by immunoblot analysis with anti-TSC2 polyclonal antibody. Tuberin bound to the GST-HtrA1wt beads, but not to glutathione-Sepharose beads containing only the GST protein, thereby confirming that there is a specific interaction between HtrA1 and TSC2. We repeated the same experiment using a specific anti-TSC1 polyclonal antibody, but no TSC1 was detectable by immunoblot analysis, so it was confirmed that there is not direct interaction between HtrA1 and TSC1 (Fig. 2B ).
HtrA1 interacts with the NH 2 -terminal region of TSC2
To better characterize the binding between HtrA1 and TSC2, we next decided to do a mapping experiment to determine the exact regions of TSC2 involved in the interaction with HtrA1. Figure 3A shows the structure of full-length TSC2 and of the deletion constructs used for mapping experiment. Each fragment was in vitro translated, [ 35 S]methionine labeled, and used for in vitro pull-down assay using GST-HtrA1wt fusion protein. As shown in Fig. 3B , the only fragment precipitated by the GST-HtrA1wt recombinant protein was the TSC2 (1-607) domain, which is the first part of the NH 2 -terminal region of the protein.
In vivo interaction between HtrA1 and TSC2
To investigate whether the interaction between HtrA1 and TSC2 occurs also in vivo, coimmunoprecipitation experiments were done using lysate from Phoenix cells transfected with pcDNA3T7Tag-HtrA1. As shown in Fig. 4A , a consistent amount of endogenous TSC2 was coimmunoprecipitated by the antibody against the epitope tag of HtrA1-tag overexpressed protein. The same result is obtained using anti-TSC2 to coimmunoprecipitate endogenous TSC2-and HtrA1-interacted protein (Fig. 4B) . This result indicates that TSC2 and HtrA1 associate in vivo, and the data are consistent with the results of the GSTHtrA1wt-binding assay.
HtrA1 localizes both in the cytoplasm and in the extracellular space of the cell
The subcellular localization of HtrA1 has been investigated by the use of immunoelectron microscopy on human placental tissue. As shown in Fig. 5 , we detected a diffuse immunopositivity for HtrA1 scattered in the cytoplasm. Interestingly, HtrA1 immunogold particles were not associated to organelles or vesicles inside the cytoplasm. Moreover, as already shown in a previous article (35) , it was clear that HtrA1 immunopositivity was present in the extracellular spaces of the same human tissues.
HtrA1 and TSC2 colocalize in the cytoplasm of Phoenix cells
To further examine whether HtrA1 and TSC2 colocalize in the cells, Phoenix cells overexpressing HtrA1 were stained using DAPI, mouse anti-T7Tag, or rabbit anti-TSC2. As shown in Fig. 6A , TSC2 localizes in the cytoplasm as well as in HtrA1. Thus, in transfected Phoenix cells, colocalization of HtrA1 and TSC2 was evident in the cytoplasm. In Fig. 6B , the same cells were transfected with the empty vector as a control. No positive staining was detectable in this case.
TSC2 phosphorylation is not necessary for the interaction with HtrA1
To investigate whether phosphorylation of TSC2 is necessary for the HtrA1/TSC2 interaction, the effect of phosphatase activity on the GST-HtrA1-binding assay was analyzed. Phoenix cells lysates were treated with PP1 before incubation with GST or GST-HtrA1wt beads. After incubation of 60 minutes at 30°C either with or without the addition of PP1, TSC2 was retained by the GSTHtrA1wt beads but not by GST alone (Fig. 7) . These data clearly show that the binding between HtrA1 and TSC2 is independent from the phosphorylation status of TSC2.
Delta-ss-mac25-HtrA1 digests TSC2 in vitro and in vivo
To explore whether TSC2 is a substrate of HtrA1, we did a digestion assay using purified recombinant human HtrA1 and human TSC2 translated in vitro and labeled with L-[
35 S]methionine. Further, we used fibronectin (as a positive control) to test the protease activity in our condition and BSA (as a negative control) to check the specificity of HtrA1 substrate recognition (Fig. 8B) . After an overnight incubation, HtrA1 completely digests TSC2 (Fig. 8A) . As TSC2 disappeared, a lot of bands of lower mass in the second lane become visible, corresponding to TSC2 digestion products. Probably, the formation of defined proteolytic bands is due to HtrA1 recognition of specific TSC2 sequences. As expected, BSA was not digested by HtrA1. cell lines leads to an increase in the endogenous levels of TSC2 as expected. Collectively, these results indicate that TSC2 is a substrate of HtrA1.
4E-BP1 is hyperphosphorylated in cells overexpressing HtrA1
We decided to overexpress both the full-length HtrA1 and the point mutant of our protein (HtrA1-S328A) into two different types of melanoma cell lines: LM (metastatic melanoma cell line) and A375 (both primary melanoma cell line, A375P, and metastatic melanoma cell line of the same cellular type, A375M).
As shown in Fig. 9A , the eukaryotic initiation factor 4E-BP1 seems to be hyperphosphorylated in all three types of cells overexpressing HtrA1 wild-type, whereas, in the cells transfected with the functional mutant of HtrA1, 4E-BP1 is clearly dephosphorylated if compared with the cells overexpressing HtrA1. Moreover, in the LM cells, 4E-BP1 seems to be hypophosphorylated also compared with the cells used as a control, which express the physiologic level of HtrA1.
S6K is hyperphosphorylated in stable clones overexpressing HtrA1 and hypophosphorylated in stable clone with downregulation of HtrA1
Immunoblot analysis, shown in Fig. 9Ba , shows that enhanced expression of HtrA1 in A2780 ovarian cancer cell line leads to diminished levels of TSC2. Consistent with this downregulation, there was an increase of p-S6K protein level. Conversely, stable downregulation of HtrA1 in SKOV3 (Fig. 9Bb) and TOV21G (Fig. 9Bc ) cells leads to an increase in the endogenous levels of TSC2 with a concomitant decrease of p-S6K form.
Discussion
HtrA1 is a serine protease ubiquitously expressed in normal human adult tissues, which is found either as a secreted protein or in the cytoplasm of the cells (35) . The transcription of this gene is highly regulated both during development and in the adult (35, 36) , and in particular, it has been shown that HtrA1 is upregulated during the progress of human pregnancy, suggesting an important role of this protein in placental formation and function (37, 38) . It is known that HtrA1 expression is decreased in progression and invasion of ovarian and endometrial cancers, melanomas, lung cancer, and mesotheliomas (10-13, 39, 40) , and it is also involved in chemotherapyinduced apoptosis (32) . Moreover, it has been shown HtrA1 has the ability to promote degeneration of extracellular matrix components, including fibronectin (6, 41), collagen (7), and amyloid precursor protein fragments involved in Alzheimer's disease (8) .
To obtain additional information about the role of HtrA1 in the cell, a yeast two-hybrid system was used to identify new possible targets of our protease. We decided to use the point mutant of full-length HtrA1 as a bait to avoid the degradation of possible targets of our protease.
It is known that the expression of HtrA1 in human embryos is dramatically upregulated from the first to the third trimester of gestation (36) . Because of the high expression of HtrA1 in the brain during embryo development, we decided to screen a human fetal brain cDNA library.
One of the proteins detected in the screening was TSC2, a tumor suppressor gene associated with tuberous sclerosis disease. Tuberous sclerosis is characterized by a variety of hamartomatous growths in different organs and tissues. The defects in cell proliferation, migration, and differentiation that these lesions display indicate that the TSC1 and TSC2 gene products participate in the control of cell growth and division (40) , and it is now recognized that the primary function of the TSC1-TSC2 complex is a critical negative regulation of the mTOR activation (27) . mTOR plays an evolutionarily conserved role in the control of cell growth (i.e., an increase in cell size), but it has also been found to regulate aspects of cell proliferation, survival, and metabolism in specific settings. In particular, mTOR acts through two well-characterized classes of downstream targets: the ribosomal S6 kinases S6K1 and S6K2, and 4E-BP1 and 4E-BP2 (42, 43) . Genetic experiments in mammalian cells showed that mTOR-mediated phosphorylation of both S6K1 and 4E-BP1 is inhibited by TSC1-TSC2 complex overexpression and is activated in cells lacking the TSC1-TSC2 dimer (43) (44) (45) (46) . As a consequence of TSC gene disruption, the mTOR signaling becomes robustly activated in a growth factor-independent manner; moreover, elevated mTOR activity has also been detected in all rodent and human tumors and tumorderived cell lines lacking TSC1 or TSC2 (47) (48) (49) (50) .
The direct interaction between HtrA1 and TSC2 was confirmed by in vitro binding experiments and by GST pull-down assays. These binding experiments indicate that HtrA1 is able to interact with TSC2 but not with the other component of the TSC complex, TSC1, thereby confirming that there is a specific interaction between HtrA1 and TSC2. It is well known that the PDZ domain is the prime site of interactions for HtrA1 (41, (51) (52) (53) . Nevertheless, our study shows the first interaction in which HtrA1 binds to another protein through the mac25 domain. Because this domain sometimes is cleaved off during HtrA1 activity (8) , it is possible to suggest that this proteolytic event is important for HtrA1 function, as it could reduce the ability of HtrA1 to interact with other proteins. Interestingly, in our experimental conditions, full-length HtrA1 is able to interact with TSC2, but the activated form of the protein, lacking ss-signal peptide and mac25 domain, is still able to proteolyse TSC2.
Evidences suggested that HtrA1 is essentially a secreted protein; most of it is located in the extracellular space and only a small percentage of the protein remains into the cells (54) . It is also true, however, that several evidences show the presence of this protease in the cytoplasm. Clawson and colleagues (55) have shown that processed forms of HtrA1 are found intracellularly and intranuclearly, and the active intranuclear form of HtrA1 shows an M r ∼29,000. Chien and colleagues (33) have reported that HtrA1 localized to the cytoplasm and associates with tubulins within the cell. They have shown that HtrA1 colocalizes with intracellular microtubules and degrades tubulins into the cytoplasm. Moreover, they observed coimmunoprecipitation of α-, β-, and γ-tubulins when endogenous HtrA1 is immunoprecipitated. In a different study, He and colleagues (56) showed, with immunoprecipitation and confocal assays, that HtrA1, as well as its 35-kDa active form, can bind to epidermal growth factor receptor on the cell membrane. Interestingly, in a few cells, the colocalization of HtrA1 and epidermal growth factor receptor in the nucleus was also observed.
Therefore, to confirm that the binding between our protease and TSC2 takes place in the cytoplasm of the cells, we decided to show this interaction also in vivo. First, by immunoelectron microscopy, we have shown that HtrA1 is indeed detected in the cytoplasm of the cells and that HtrA1 immunogold particles were not associated to organelles or vesicles inside the cytoplasm. Moreover, endogenous TSC2 associated with HtrA1 and was coimmunoprecipitated in Phoenix cell lysate. Finally, colocalization analysis with immunofluorescence showed that HtrA1 and TSC2 interact into the cytoplasm of the cells.
TSC2 is phosphorylated at multiple amino acid residues, and this phosphorylation is important for the properties of binding of TSC2. Therefore, we investigated if the binding between HtrA1 and TSC2 is independent by the phosphorylation state of TSC2. Indeed, our data indicate that this posttranscriptional regulation of TSC2 does not affect the binding of HtrA1.
The role of HtrA1 as a protease capable to cleave extracellular proteins such as fibronectin, collagen, or components of cartilage is known (5, 7) . In the present report, we identified the intracellular protein TSC2 as a substrate of HtrA1. By using the purified activated form of HtrA1, called delta-ss-mac25-HtrA1, we have shown that HtrA1 effectively degraded in vitro-translated TSC2, generating fragments of various sizes with low molecular weight. The same phenomenon was found in vivo using three different cellular systems engineered to overexpress or silence HtrA1.
As previously described, we found that the binding site of HtrA1 on TSC2 is in the same region in which TSC1 interacts with TSC2 during the dimer formation; furthermore, our protease is able to digest TSC2. The observation that TSC2, when phosphorylated, translocates to the cytoplasm (57) further supports the idea that HtrA1 interacts with TSC2 predominantly within cells due to this mechanism of phosphorylated TSC2 becoming cytosolic. It might be that in particular physiologic conditions in which HtrA1 is present in high level in the cells, TSC2 is degraded, and the downstream factors of the pathway are activated as depicted in the cartoon in Fig. 10 .
To confirm our hypothesis, we decided to investigate if upregulation or downregulation of HtrA1 in vitro is able to cause altered expression of the factors involved in the TSC pathway. In the first experiment, we used two different types of melanoma cell lines (A375 and LM). In our experimental conditions, 4E-BP1 was hyperphosphorylated in cells overexpressing HtrA1, whereas the level of the same molecule was lower when we used the point mutant form of HtrA1 (HtrA1-S328A) to transfect the cells, thus confirming that the proteolytically active form of HtrA1 is able to interfere with the expression of downstream targets of TSC2. Therefore, we decided to investigate in a different experimental setting the effects of HtrA1 upregulation or downregulation on S6K phosphorylation status. Indeed, we also found that this downstream effector of TSC2 is hyperphosphorylated when HtrA1 is upregulated and, coherently, hypophosphorylated when HtrA1 is silenced.
In conclusion, in our study, we have shown for the first time an interaction involving TSC2 and HtrA1; moreover, we have shown that HtrA1 is able to digest TSC2 both in vitro and in vivo. The functional role of this interaction is still unclear, but we can speculate that, in particular physiologic or pathologic conditions, HtrA1 degrades TSC2 and activates the downstream targets. Considering that HtrA1 levels are significantly increased during embryogenesis, we speculate that one of the targets of HtrA1 activity during fetal development is the TSC2-TSC1 pathway. Further experiments are indeed required to further define this interaction and to investigate its role during differentiation and tumor progression.
